32 results on '"Ma S"'
Search Results
2. 375P The co-mutations and genetic features of BRAF-mutated gene mutations in a large Chinese MSS colorectal cancer cohort
3. 309P A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (EBC) in China: Interim analysis of the NER-Tree study
4. 1440P Neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma with camrelizumab, albumin-paclitaxel, carboplatin and apatinib (GASTO-1093): A single-arm, open-label, phase II trial
5. 635P The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumors
6. 118TiP A multicenter, randomized, double-blind, placebo-controlled phase III trial of camrelizumab plus chemotherapy with or without radiation therapy (RT) as first-line treatment for patients with brain metastatic non-small cell lung cancer (BM-NSCLC; CTONG2003): Trial in progress
7. 2O Penpulimab, an IgG1 anti-PD-1 antibody with Fc-engineering to eliminate effector functions and with unique epitope and binding properties
8. 1657P Anlotinib plus irinotecan or docetaxel in small-cell lung cancer (SCLC) relapsed within six months: Updated results from a single-arm phase II study
9. P-296 Establishment of adoptive cell therapy with tumor-infiltrating lymphocytes for liver and oesophageal cancer
10. 1885P Pexa-vec (thymidine kinase-deactivated vaccinia virus plus GM-CSF) in combination with cemiplimab (REGN2810; ANTI-PD-1) for metastatic or unresectable renal cell carcinoma REN026: Results from a phase II study
11. 180P An HLA-diet-oriented system unveiling organ-specific occurrence of multiple primary cancers (MPC) with prevention strategy: A large cohort study of 47,550 cancer patients
12. 787P A NGS panel for molecular classification of endometrial carcinoma
13. 2348P High-throughput screening reveals GSK1838705A as a potent inhibitor of CAFs-promoted tumor progression in esophageal squamous cell carcinoma
14. 394P Apatinib plus etoposide capsules as third-line or further-line treatment for extensive stage small cell lung cancer patients: A multicenter, single arm, phase II clinical trial
15. 1262P Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033
16. 929P Anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: An interim analysis of a phase II clinical trial
17. 1376P Anlotinib combination with docetaxol for patients with previously treated advanced non-small cell lung cancer: A phase II, single-arm trial
18. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years
19. 1095P Concomitant genetic alterations predicted response to alectinib in patients with ALK-rearranged non-small cell lung cancer: A real word study in China
20. A multi-center integrative study on cancer predisposition genes in Chinese patients with epithelial ovarian carcinoma
21. Chemotherapeutic hyperthermic intraperitoneal perfusion following radical D2 resection in the treatment of advanced gastric cancer
22. Application of next generation sequencing in pleural effusion molecular profiling using Oncomine™ lung cell-free total nucleic acid research assay
23. First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial
24. Influence of plasma T790M mutation on clinical decision after 1st generation EGFR-TKI resistance in a Real-world study
25. 1012P - A multi-center integrative study on cancer predisposition genes in Chinese patients with epithelial ovarian carcinoma
26. Frequency and abundance of plasma T790M mutation associated with failure patterns of EGFR-mutant NSCLC treated with tyrosine kinase inhibitors
27. 469P - Application of next generation sequencing in pleural effusion molecular profiling using Oncomine™ lung cell-free total nucleic acid research assay
28. 1332P - Influence of plasma T790M mutation on clinical decision after 1st generation EGFR-TKI resistance in a Real-world study
29. 1052PD - First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial
30. P-019 - Chemotherapeutic hyperthermic intraperitoneal perfusion following radical D2 resection in the treatment of advanced gastric cancer.
31. 582P Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.
32. 523P Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.